secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001641172-25-001045
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025
---------------------------------------------------------------------------

- Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.
- Trial evaluates THIO sequenced with cemiplimab in advanced NSCLC patients after 2+ prior therapies.
- Poster copy filed as Exhibit 99.1 and posted on company website; no specific numeric results in 8-K text.
- Data disclosure under Regulation FD; forward-looking statements caution against undue reliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/0001641172-25-001045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer